Alagebrium chloride

Research use only, not for human use.

Alagebrium Chloride is an advanced glycation end product (AGE) inhibitor and has proven effective in reducing systolic blood pressure and providing therapeutic benefit for patients with diastolic.

Alagebrium Chloride is an advanced glycation end product (AGE) inhibitor and has proven effective in reducing systolic blood pressure and providing therapeutic benefit for patients with diastolic.(In Vitro):Alagebrium chloride is an advanced glycation end product (AGE) inhibitor. Endothelial cell (EC) proliferation is increased for all groups receiving Alagebrium (ALT-711), particularly when seeded on matrix from the AAo of obese (ZO) and diabetic (ZD) rats.(In Vivo):Blood pressure is not affected by treatment with Alagebrium. In diabetic RAGE apoE double-KO mice, treatment with Alagebrium is associated with a modest reduction in renal mass and reduces hyperfiltration compare with nontreated mice. Treatment with Alagebrium in diabetic RAGE apoE double-KO mice is associated with a further reduction in glomerular collagen IV levels, approaching levels observed in control mice. Body weight, heart rate (HR), and mean blood pressure (BP) are similar in Zucker lean (ZL), obese (ZO), and diabetic (ZD) groups in the absence or presence of Alagebrium (ALT-711). Alagebrium increases blood flow (BF) in ZO rats but reduces distal vascular resistance in ZD rats. A decrease in neointimal hyperplasia (NH) intrastrut thickness as a function of local radius is found in all groups with Alagebrium treatment.A significant increase in TGF-β expression is also found in the AAo of ZL rats treated with Alagebrium.

Alagebrium chloride is an advanced glycation end product (AGE) inhibitor. Endothelial cell (EC) proliferation is increased for all groups receiving Alagebrium (ALT-711), particularly when seeded on matrix from the AAo of obese (ZO) and diabetic (ZD) rats.

Blood pressure is not affected by treatment with Alagebrium.? In diabetic RAGE apoE double-KO mice, treatment with Alagebrium is associated with a modest reduction in renal mass and reduces hyperfiltration compare with nontreated mice. Treatment with Alagebrium in diabetic RAGE apoE double-KO mice is associated with a further reduction in glomerular collagen IV levels, approaching levels observed in control mice. Body weight, heart rate (HR), and mean blood pressure (BP) are similar in Zucker lean (ZL), obese (ZO), and diabetic (ZD) groups in the absence or presence of Alagebrium (ALT-711). Alagebrium increases blood flow (BF) in ZO rats but reduces distal vascular resistance in ZD rats. A decrease in neointimal hyperplasia (NH) intrastrut thickness as a function of local radius is found in all groups with Alagebrium treatment.? A significant increase in TGF-β expression is also found in the AAo of ZL rats treated with Alagebrium.

ALT711

Others

Other Targets

AGE

Metabolic Disease

Diabetic nephropathies; Diastolic heart failure; Erectile dysfunction; Heart failure; Hypertension

341028-37-3

267.77

C13H14ClNOS

>98% (HPLC)

DMSO:25 mg/mL (93.36 mM)

[Cl-].Cc1sc[n+](CC(=O)c2ccccc2)c1C

——

(-20℃)

With Ice Pack

≥ 2 years